Adage Capital Partners’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-800,000
| Closed | -$10.1M | – | 865 |
|
|
2024
Q4 | $10.1M | Sell |
800,000
-100,000
| -11% | -$1.27M | 0.02% | 602 |
|
|
2024
Q3 | $12.5M | Buy |
+900,000
| New | +$12.5M | 0.02% | 570 |
|
|
2024
Q2 | – | Sell |
-159,000
| Closed | -$2.63M | – | 884 |
|
|
2024
Q1 | $2.63M | Buy |
159,000
+9,000
| +6% | +$149K | 0.01% | 758 |
|
|
2023
Q4 | $2.19M | Sell |
150,000
-886,599
| -86% | -$12.9M | ﹤0.01% | 738 |
|
|
2023
Q3 | $12.7M | Sell |
1,036,599
-1,405,901
| -58% | -$17.3M | 0.03% | 517 |
|
|
2023
Q2 | $29.2M | Buy |
2,442,500
+1,702,500
| +230% | +$20.3M | 0.06% | 308 |
|
|
2023
Q1 | $9.89M | Sell |
740,000
-2,560,000
| -78% | -$34.2M | 0.02% | 620 |
|
|
2022
Q4 | $71M | Buy |
3,300,000
+260,000
| +9% | +$5.6M | 0.17% | 148 |
|
|
2022
Q3 | $60.9M | Buy |
3,040,000
+293,175
| +11% | +$5.87M | 0.15% | 157 |
|
|
2022
Q2 | $49.2M | Buy |
2,746,825
+2,570,976
| +1,462% | +$46M | 0.11% | 193 |
|
|
2022
Q1 | $1.74M | Buy |
175,849
+65,849
| +60% | +$653K | ﹤0.01% | 907 |
|
|
2021
Q4 | $1.85M | Buy |
110,000
+20,000
| +22% | +$337K | ﹤0.01% | 875 |
|
|
2021
Q3 | $2.14M | Buy |
+90,000
| New | +$2.14M | ﹤0.01% | 892 |
|